Skip to content

CalAmp CAMP Proceeds From Issuance Of Warrants

Proceeds From Issuance Of Warrants at other companies

Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$56.25K
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$5.86M

Other financials

Income statement

See full
Revenue$1.3M+50.8%
Operating income-$13.1M+0.2%
Net income-$18.3M-47.4%
EPS (diluted)-$0.32+48.4%

Balance sheet

See full
Cash & equivalents$100.8M+97.9%
Total debt$2.1M-73.2%
Total equity$30.9M-40.1%
Total assets$105.5M+68.0%

Cash flow

See full
Operating cash flow-$11.0M+23.1%
CapEx--100%
Free cash flow-$11.0M+24.6%

Valuation

See full
Market cap$226.92M+666%
Enterprise value$128.2M-3,860%
P/S57.7×+47.8×

Profitability

See full
Operating margin-1,335.2%-512pp
Net margin-2,193.7%-581pp
FCF margin-1,254%

Returns & leverage

See full
Return on equity-209.3%
Debt / equity0.1×-0.1×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by CalAmp in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfWarrants.

The official record: CalAmp’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CalAmp's proceeds from issuance of warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CalAmp's proceeds from issuance of warrants?
CalAmp (CAMP) reported proceeds from issuance of warrants of $900.25K in Q4 2025.
What does proceeds from issuance of warrants mean?
This represents the cash inflows received from the issuance of warrants, which grant holders the right to purchase company stock at a specified price. It serves as a source of capital that may lead to future dilution of existing shareholders. Investors analyze this to understand the company's strategy for raising capital and the potential impact on future equity structure.